FASN and diffuse large B-cell lymphoma: Selective inhibition of FASN by the novel drug, Fasnall, was demonstrated in a panel of DLBCL cell lines, implying the therapeutic potential of interference with FA synthesis, especially in a subset of DLBCL cells that preferentially utilize de novo FA biosynthesis [356].